Pterostilbene is a dimethylated resveratrol analog found in blueberries that has significantly better oral bioavailability. Here is what that pharmacokinetic advantage means for the evidence — and what it does not yet prove.
Pterostilbene differs from resveratrol in one key structural feature: two hydroxyl groups are replaced with methoxy groups. This dimethylation dramatically increases lipophilicity and blocks the rapid phase II glucuronidation that limits resveratrol's oral bioavailability to approximately 1%.
The result is oral bioavailability of approximately 80% in animal studies, with a half-life roughly seven times longer than resveratrol. Pterostilbene is found naturally in blueberries and grapes, but at concentrations far too low to achieve therapeutic plasma levels from diet alone.
The logical hypothesis is that pterostilbene does what resveratrol was supposed to do — activate SIRT1, AMPK, and downstream longevity pathways — but actually reaches the target tissues at meaningful concentrations. The question is whether the human evidence supports this.
The Riche 2014 finding of increased LDL at 100mg/d is the most important clinical data point in the pterostilbene literature and is frequently omitted from supplement company discussions of the compound. An LDL increase of 10+ mg/dL at the dose range being commercially promoted warrants careful consideration in any patient with existing cardiovascular risk factors.
This may be a dose-dependent effect — the 50mg arm did not show the same signal. Whether the 50mg dose is sufficient to achieve longevity-relevant SIRT1 activation is unknown. This is a genuine clinical uncertainty that should be communicated to patients.
Pterostilbene has a stronger pharmacokinetic profile than resveratrol and a modestly positive blood pressure signal in one small RCT. The evidence tier is Emerging — marginally better than resveratrol's Insufficient, based on the bioavailability advantage and the blood pressure data.
The LDL concern at 100mg/d is a meaningful differentiator from resveratrol and should not be dismissed. Neither compound has been tested in the NIA ITP program for lifespan extension in mice. Neither has hard human longevity outcome data. The pharmacokinetic advantage of pterostilbene is real; whether it translates to a meaningful clinical advantage for longevity remains unproven.
This information is provided for educational reference only and does not constitute medical advice or a treatment recommendation.